Objective To explore the clinical efficacy of Zhiling Capsules combined with Tenofovir Alafenamide Fumarate Tablets in treatment of chronic hepatitis B.Methods 112 Patients with chronic hepatitis B in The 910th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army were divided into control and treatment group according to the random number table method,56 cases in each group.Patients in the control group took Tenofovir alafenamide Fumarate Tablets,1 tablets each time,once daily.Patients in the treatment group po administered with Zhiling Capsules,2 capsules each time,3 times daily.Two groups received continuous treatment for 6 months.Therapeutic effects,serum indicators,and lymphocyte indicators between two groups were compared.Results The total effective rate of the treatment group after treatment was higher than that of the control group(94.64%vs 82.14%,P<0.05).The HBV-DNA negative conversion rate,HBeAg/anti-HBe conversion rate,and HBeAg negative conversion rate in the treatment group were higher than those in the control group(P<0.05).TBil,ALT,and AST in two groups were significantly decreased(P<0.05),and TBil,ALT,and AST in the treatment group after treatment were lower than those in the control group(P<0.05).CD3+,CD4+,and CD8+in the two groups were decreased,but CD4+/CD8+was increased(P<0.05).CD3+,CD4+,and CD8+in the treatment group were lower than those in the control group,but CD4+/CD8+was higher than those in the rtreatment group(P<0.05).Conclusion Zhiling Capsules combined with Tenofovir Alafenamide Fumarate Tablets can improve the therapeutic effect of patients with chronic hepatitis B,improve liver function,promote HBeAg negative conversion,and further regulate immune function.
万方数据
